Liver Transplantation and Uveal Malignant Melanoma

Oslo University Hospital2 enrolled

Overview

Patients with uveal malignant melanoma with liver metastases have median survival of less than 12 months. There is no established treatment showing increased overall survival. The study will determine if liver transplantation will result in long term survival in patients with liver metastases from uveal malignant melanoma.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Uveal Malignant Melanoma

Interventions

Liver transplantationPROCEDURE

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Uveal malignant melanoma * Liver metastases * ECOG 0-1 Exclusion Criteria: * Extra hepatic disease * Previous other malignancy * Previous organ transplantation

Locations (1)

Oslo University Hospital

Oslo, Norway

Outcomes

Primary Outcomes

Over all survival

Patient survival after livertransplantation

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.